Skip to main content
Clinical Trials/NL-OMON22426
NL-OMON22426
Not yet recruiting
Not Applicable

nderstanding treatment patterns and patient preferences towards TPO-RAs (thrombopoietin receptor agonists) in adults with ITP (immune thrombocytopenia): The TRAPeze study

Sobi0 sites150 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Immune Thrombocytopenia
Sponsor
Sobi
Enrollment
150
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational non invasive

Investigators

Sponsor
Sobi

Eligibility Criteria

Inclusion Criteria

  • A subject must fulfill the following criteria in order to be included in the study:
  • 1\.Men or women \=18 years of age
  • 2\.Formal diagnosis of primary ITP according to the ASH and ICR guidelines \[14, 25]
  • 3\.Currently or have previously received a TPO\-RA (either eltrombopag and/or romiplostim) in the last 12 months
  • 4\.Have been treated with a TPO\-RA for a minimum of 3 months, with at least some of the treatment received in the last 12 months
  • 5\.Provide written informed consent
  • 6\.Ability to understand and respond in English; this does not need to be the participants’ first language or even their own language if they wish to use their own translator. If recruitment appears to be limited by this, then translations of the survey will be made. Further plans for deployment will also see the survey translated into Dutch, French, German, Italian and Spanish

Exclusion Criteria

  • The presence of any of the following will exclude a subject from inclusion in the study:
  • 1\.Known secondary immune thrombocytopenia
  • 2\.Foreseeable inability to cooperate with given instructions or study procedures
  • 3\. Inability to give consent

Outcomes

Primary Outcomes

Not specified

Similar Trials